

Supplementary Table 1: Characteristics of study participants at study entry, stratified by reduced, preserved, or recovered left ventricular ejection fraction; summaries presented as n (%) unless otherwise noted as median (interquartile range).

	Reduced LVEF n = 1141	Preserved LVEF n = 106	Recovered LVEF n = 138
<i>Demographic characteristics</i>			
Age, years, median (IQR)	57 (47, 65)	61 (51, 72)	57 (51, 66)
Male sex	801 (70.2)	50 (47.2)	70 (50.7)
Race			
Caucasian	846 (74.1)	70 (66.0)	113 (81.9)
African American	249 (21.8)	33 (31.1)	24 (17.4)
Other	46 (4.0)	3 (2.8)	1 (0.7)
<i>Medical history and risk factors</i>			
History of diabetes	342 (30.0)	29 (27.4)	37 (26.8)
History of hypertension	664 (58.2)	70 (66.0)	83 (60.1)
History of hyperlipidemia	728 (63.8)	66 (62.3)	86 (62.3)
Tobacco use			
Current	115 (10.1)	5 (4.8)	13 (9.6)
Former	620 (54.5)	56 (53.3)	68 (50.0)
Never	403 (35.4)	44 (41.9)	55 (40.4)
<i>Heart failure characteristics</i>			
NYHA functional classification			
I	168 (14.7)	27 (25.5)	34 (24.6)
II	521 (45.7)	53 (50.0)	70 (50.7)
III	361 (31.6)	21 (19.8)	27 (19.6)
IV	91 (8.0)	5 (4.7)	7 (5.1)
Ischemic cardiomyopathy etiology	393 (34.4)	15 (14.2)	23 (16.7)
Cardiac resynchronization therapy	338 (29.6)	4 (3.8)	22 (15.9)
Defibrillator use	557 (48.8)	8 (7.5)	32 (23.2)
<i>Clinical measures, median (IQR)</i>			
LVEF, %	25 (18, 35)	64 (60, 70)	55 (50, 60)
Body mass index, kg/m <sup>2</sup>	28 (25, 33)	29 (25, 36)	29 (25, 34)

Systolic blood pressure, mmHg	110 (98, 123)	125 (111, 139)	117 (104, 130)
Diastolic blood pressure, mmHg	70 (60, 78)	70 (62, 79)	70 (62, 78)
Creatinine, mg/dL	0.93 (0.77, 1.27)	0.90 (0.77, 1.36)	0.84 (0.71, 1.15)
Estimated GFR, mL/min/1.73 m <sup>2</sup>	67 (50, 84)	63 (48, 81)	71 (56, 83)
<i>Medication use</i>			
ACE inhibitors or ARBs	1036 (90.8)	64 (60.4)	115 (83.3)
Aldosterone antagonists	427 (37.4)	14 (13.2)	31 (22.5)
Beta blockers	1043 (91.4)	70 (66.0)	117 (84.8)
Digoxin	509 (44.6)	5 (4.7)	36 (26.1)
Hydralazine or nitrates	203 (17.8)	14 (13.2)	21 (15.2)
<i>Biomarkers, median (IQR)</i>			
Galectin-3, ng/mL	18.0 (13.4, 23.6)	17.2 (13.6, 24.3)	16.0 (13.4, 20.8)
High-sensitivity ST2, ng/mL	27.3 (19.9, 40.8)	27.5 (21.3, 37.9)	26.0 (18.5, 36.6)
Troponin-I			
Detectable, n (%)	782 (68.5)	55 (51.9)	65 (47.1)
Troponin-I, ng/mL, median (IQR) <sup>a</sup>	0.02 (0.01, 0.04)	0.01 (0.01, 0.04)	0.01 (0.01, 0.03)
BNP, pg/mL	215 (67, 681)	84 (41, 240)	66 (25, 172)

IQR, interquartile range, presented as 25<sup>th</sup> and 75<sup>th</sup> percentile; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; GFR, glomerular filtration rate; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ST2, soluble toll-like receptor-2; BNP, B-type natriuretic peptide.

<sup>a</sup> Among those participants with a detectable troponin-I.